Month: April 2026

For people living with schizophrenia who may find daily disease management overwhelming due to fragmented support and resources, Home Ground™ Schizophrenia Community is a centralized destination that delivers peer-driven insights, tools and connection  Home Ground™ was developed in collaboration with people living with schizophrenia, care partners and mental health advocacy groups to help support wellbeing through shared experience As a leader in neuroscience, Teva is committed to supporting people living with complex mental health conditions through practical resources to help navigate the care journeyPARSIPPANY, N.J. and TEL AVIV, Israel, April 15, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the launch of Home Ground™...

STOCK EXCHANGE RELEASE 15 April 2026, at 3:00 P.M. EEST DECISIONS OF THE ORGANISATIONAL MEETING OF HARVIA PLC’S BOARD OF DIRECTORS ON 15 APRIL 2026 Catharina Stackelberg-Hammarén was elected the Chair and Markus Lengauer was elected the Deputy Chair of the Board of Directors at the Board of Directors’ organisational meeting that took place today after Harvia Plc’s Annual General Meeting. The Board of Directors elected from among its members Petri Castrén (Chair), Hille Korhonen, Markus Lengauer and Martin Richter as members of the Audit Committee. The Board of Directors elected from among its members Catharina Stackelberg-Hammarén (Chair), Anders Holmén and Olli Liitola as members of the Personnel and Remuneration Committee. Independence of the members of the Board of Directors The Board of Directors assessed the independence of its members...

SYDNEY, AUSTRALIA, April 15, 2026 (GLOBE NEWSWIRE) — Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company targeting cancer and autoimmune diseases, today announces that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for eftilagimod alfa (“efti”) for the treatment of Soft Tissue Sarcoma (STS), a rare cancer with significant unmet medical need. The FDA’s Orphan Drug Designation program is designed to encourage development of therapies for rare diseases affecting fewer than 200,000 people in the United States. Benefits of ODD may include regulatory support, potential tax credits, fee exemptions, and seven years of market exclusivity upon approval. This designation recognises the potential therapeutic relevance of efti in STS, supported...

GARDEN CITY, N.Y., April 15, 2026 (GLOBE NEWSWIRE) — Beyond Air, Inc. (NASDAQ: XAIR), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve patients’ lives, today announced that Robert Goodman, Chief Executive Officer, and Dan Moorhead, Chief Financial Officer of Beyond Air, will participate in the D. Boral Capital Global Conference 2026, which is being held on Thursday, May 7th, at The Plaza Hotel in New York.Conference    Format:   One-on-one meetingsConference Dates:   May 7thParticipants:   Robert Goodman, CEO, and Dan Moorhead, CFO of Beyond Air     If you are interested in requesting a one-on-one meeting at the conference, please contact your D. Boral Capital representative to schedule accordingly. About Beyond Air, Inc. Beyond Air...

Financing led by Sirenia Capital Management LP advances Traws Pharma’s influenza program through a human challenge trial for tivoxavir marboxil in the United KingdomNEWTOWN, Pa., April 15, 2026 (GLOBE NEWSWIRE) — Traws Pharma, Inc. (NASDAQ: TRAW, “Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced that it has entered into a securities purchase agreement with new and existing institutional and accredited investors for a private investment in public equity (“PIPE”) financing expected to provide approximately $10.0 million in gross proceeds at closing. The financing will position Traws Pharma to complete the Challenge trial, in the United Kingdom (“Challenge Trial”) and includes...

Manufacturing Agreement Advances Metformin Ophthalmology Platform Toward First-in-Human Clinical Study Palm Beach Gardens, FL, April 15, 2026 (GLOBE NEWSWIRE) — Curative Biotechnology, Inc. (OTC: CUBT, CUBTD) (“Curative” or the “Company”), a development-stage biomedical company focused on novel therapies for degenerative eye diseases, today announced that it has engaged Sterling Pharmaceutical Services, LLC, a U.S.-based contract development and manufacturing organization (CDMO), to manufacture clinical supply of its metformin-based topical ophthalmic formulation. Sterling Pharmaceutical Services, LLC, located in Dupo, Illinois, specializes in formulation development and manufacturing of sterile pharmaceutical products and will support production of topical metformin ophthalmic drops intended for use in the Company’s planned first-in-human...